PHKB抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08619(PHKB Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P08619(PHKB Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The PHKB antibody targets the β subunit of phosphorylase kinase (PhK), a critical enzyme in glycogen metabolism. PhK, composed of four subunits (α, β, γ, δ), regulates glycogen breakdown by activating glycogen phosphorylase via phosphorylation. The β subunit (PHKB) plays a regulatory role, modulating the enzyme’s activity and stability through calcium/calmodulin-dependent mechanisms. Mutations in the PHKB gene are linked to glycogen storage disease type IX (GSD IX), a rare metabolic disorder characterized by hepatomegaly, growth delays, and hypoglycemia due to impaired glycogenolysis.

PHKB antibodies are essential tools in research and diagnostics. They enable the detection and quantification of PHKB expression in tissues like liver and muscle, aiding in the study of GSD IX pathophysiology. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry, and ELISA to assess protein levels, localization, and post-translational modifications. Additionally, they help investigate PHKB’s interactions within the PhK complex and its role in cellular energy regulation. Commercially available PHKB antibodies are typically raised in rabbits or mice, validated for specificity and sensitivity. Their application extends to exploring metabolic pathways, drug development, and understanding molecular mechanisms underlying glycogen-related disorders. Accurate detection of PHKB expression or dysfunction using these antibodies supports both basic research and clinical diagnostics, offering insights into therapeutic strategies for metabolic diseases.